CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 25 filers reported holding CATABASIS PHARMACEUTICALS IN in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $1,996,000 | -17.4% | 2,494,827 | -1.0% | 0.00% | – |
| Q2 2018 | $2,416,000 | +128.4% | 2,519,315 | +330.9% | 0.00% | – |
| Q1 2018 | $1,058,000 | +27.6% | 584,715 | +5.0% | 0.00% | – |
| Q4 2017 | $829,000 | +15.0% | 556,781 | +63.7% | 0.00% | – |
| Q3 2017 | $721,000 | +113.9% | 340,074 | +43.4% | 0.00% | – |
| Q2 2017 | $337,000 | -42.9% | 237,180 | -35.7% | 0.00% | – |
| Q1 2017 | $590,000 | -27.2% | 368,893 | +64.4% | 0.00% | – |
| Q4 2016 | $810,000 | -41.4% | 224,325 | -0.0% | 0.00% | – |
| Q3 2016 | $1,382,000 | +174.2% | 224,404 | +64.9% | 0.00% | – |
| Q2 2016 | $504,000 | -31.3% | 136,099 | -6.6% | 0.00% | – |
| Q1 2016 | $734,000 | -29.1% | 145,672 | +11.6% | 0.00% | – |
| Q4 2015 | $1,035,000 | -99.4% | 130,495 | -97.2% | 0.00% | -100.0% |
| Q3 2015 | $168,937,000 | +15629.7% | 4,732,472 | +5277.8% | 0.01% | – |
| Q2 2015 | $1,074,000 | – | 88,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 2,857,667 | $23,118,000 | 12.93% |
| Clarus Ventures, LLC | 2,752,488 | $22,268,000 | 12.81% |
| Camber Capital Management LP | 1,000,000 | $8,090,000 | 0.69% |
| Rhenman & Partners Asset Management AB | 300,427 | $2,430,000 | 0.39% |
| SPHERA FUNDS MANAGEMENT LTD. | 327,476 | $2,595,000 | 0.33% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 628,482 | $5,084,000 | 0.20% |
| Spark Investment Management LLC | 32,500 | $263,000 | 0.03% |
| Tower Research Capital LLC (TRC) | 10,764 | $87,000 | 0.01% |
| VANGUARD GROUP INC | 4,732,472 | $168,937,000 | 0.01% |
| Alyeska Investment Group, L.P. | 40,220 | $325,000 | 0.00% |